Table 2 Outcomes as per donor source in univariate analysis.

From: Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT

 

MSD

HD

p

ANC engraftment (day 28)

95% (94–96%)

80% (76–84%)

p < 0.001

Median (95% CI)

16 (16–17)

20 (19–21)

 

Platelet engraftment (day 100)

94% (93–96%)

75% (71–80%)

p < 0.001

Median (95% CI)

14 (14–15)

28 (27–31)

 

Primary graft failure (2 yr)

2% (1–2%)

10% (7–12%)

p < 0.001

Secondary graft failure (2 yr)

4% (3–5%)

3% (2–5%)

0.8

aGvHD II-IV (day 100)

21% (19–24%)

24% (20–28%)

0.3

aGvHD III–IV (day 100)

10% (8–11%)

10% (7–13%)

0.7

cGvHD (2 yr)

44% (41–47%)

32% (28–37%)

p < 0.001

Limited cGvHD (2 yr)

23% (20–25%)

14% (10–18%)

p < 0.001

Extensive cGvHD (2 yr)

18% (15–20%)

17% (14–21%)

0.9

OS (2 yr)

58% (55–61%)

50% (45–55%)

p < 0.001

PFS (2 yr)

51% (48–54%)

47% (42–53%)

0.029

Relapse (2 yr)

29% (26–32%)

23% (18–27%)

0.016

NRM (2 yr)

20% (17–22%)

30% (25–35%)

p < 0.001

GRFS (2 yr)

26% (23–29%)

31% (25–37%)

0.9

  1. MSD matched sibling donor, haplo haploidentical donor, ANC absolute neutrophil counts, HCT Haematopoeitic cell transplant, GVHD graft vs host disease, OS overall survival, GRFS GVHD free relapse free survival, NRM non-relapse mortality, yr year, PFS progression free survival.
Back to article page